Kairos Therapeutics
2013
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
Description
Developer of antibody-drug conjugate therapeutics for cancer. The company provides an antibody-drug conjugate platform that enables development of therapeutics for the treatment of multiple forms of cancer.
Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 2405 Wesbrook Mall
- Fourth Floor
- Vancouver, British Columbia V6T 1Z3
- Canada
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Kairos Therapeutics’s full profile, request a free trial.
Kairos Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 22-Mar-2016 | Completed | Startup | |||
| 1. Early Stage VC | 12-Dec-2013 | Completed | Startup |
Kairos Therapeutics Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ADC Biotechnology | Venture Capital-Backed | Chester, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Private Equity-Backed | Abingdon, United Kingdom | 00 | 000.00 | 0000000 0000 | 000.00 |
| 0000000 000 | Formerly PE-Backed | Cambridge, MA | 000 | 000000&0 | ||
| 0000000 | Formerly PE-Backed | Beijing, China | 0000 | 00.000 | 000000000 | 00.000 |
Kairos Therapeutics Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| CDRD Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |